monopar.jpg
Monopar Announces First Patient Dosed in its Phase 2b/3 VOICE Trial Evaluating Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
February 16, 2021 07:30 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
ibn-iw-globe-2.png
InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring AzurRx Biopharma Inc. President & CEO James Sapirstein
November 24, 2020 08:17 ET | InvestorBrandNetwork (IBN)
LOS ANGELES, Nov. 24, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment...
logo.jpg
ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01
September 10, 2020 05:46 ET | ImCheck Therapeutics SAS
ImCheck Achieves Initial Positive Independent Safety Reviewand Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01                        Company Receives FDA Approval for US IND ...
logo.gif
Auris Medical Announces Positive Interim Data from TRAVERS Phase 2 Study with AM-125 in Vertigo
September 03, 2020 08:30 ET | Auris Medical AG
Dose dependent improvement in balance tests over placebo in Part A of TRAVERS trialImprovement 1.9 to 2.4 times greater with highest dose than with placeboTrial to proceed with Part B to test AM-125...
logo.gif
Auris Medical Announces Completion of Enrollment into First Part of TRAVERS Phase 2 Study with AM-125 in Vertigo
July 29, 2020 08:30 ET | Auris Medical AG
Dose escalation completed as last patient enrolled into Part A of TRAVERS studyInterim results to be announced in Q3 of 2020 Hamilton, Bermuda, July 29, 2020 – Auris Medical Holding Ltd. (NASDAQ:...
Screen Shot 2019-05-07 at 1.08.38 PM.png
Eric Traut First Attorney to Receive Project Youth Barnes Award and ABOTA Trial Lawyer of the Year Honor in Same Year
December 09, 2019 06:00 ET | Eric Traut
SANTA ANA, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Attorney Eric Traut will be the first attorney ever to receive the highest award from Orange County American Board of Trial Advocates and the...
Cavitation Technologies, Inc.png
Cavitation Technologies Announces Update on Produced Water Treatment System Trial
August 26, 2019 09:00 ET | Cavitation Technologies, Inc
CHATSWORTH, CA, Aug. 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Cavitation Technologies, Inc. (CTi) (OTCQB: CVAT) (BERLIN: WTC),  is pleased to announce its completion of successful trials of...
Kannalife_logo_w-Tag.png
Kannalife Inc. Publishes New Research on Chemotherapy-Induced Peripheral Neuropathy
May 21, 2019 09:00 ET | Kannalife, Inc.
DOYLESTOWN, Pa., May 21, 2019 (GLOBE NEWSWIRE) -- Kannalife, Inc. (OTC:KLFE), Kannalife (“Kannalife” or “the Company”), a biopharmaceutical company leading innovation in research, development and...
logo_new.jpg
ObsEva SA Reports Consistent Long-Term Findings from Phase 2b EDELWEISS trial of Linzagolix for Endometriosis-Associated Pain
May 03, 2019 01:00 ET | ObsEva SA
                     Geneva, Switzerland and Boston, MA – May 3, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and...
logo_new.jpg
ObsEva SA Reports Further Infant Follow-up Data from IMPLANT2 Trial Echoing Favorable Safety Profile of Nolasiban in IVF
April 29, 2019 01:00 ET | ObsEva SA
Geneva, Switzerland and Boston, MA – April 29 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...